( S ) Few studies of medical therapies for endometriosis report outcomes that are relevant to patients , and many women gain only limited or intermittent benefit from treatment
OBJECTIVE To assess patient response rates to medical therapies used to treat endometriosis-associated pain .
Elagolix, an Oral GnRH Antagonist, Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis
This r and omized double-blind study , with 24-week treatment and 24-week posttreatment periods , evaluated the effects of elagolix ( 150 mg every day , 75 mg twice a day ) versus subcutaneous depot medroxyprogesterone acetate ( DMPA-SC ) on bone mineral density ( BMD ) , in women with endometriosis-associated pain ( n = 252 ) . All treatments induced minimal mean changes from baseline in BMD at week 24 ( elagolix 150 mg : −0.11%/−0.47 % , elagolix 75 mg : −1.29%/−1.2 % , and DMPA-SC : 0.99%/−1.29 % in the spine and total hip , respectively ) , with similar or less changes at week 48 ( posttreatment ) . Elagolix was associated with improvements in endometriosis-associated pain , assessed with composite pelvic signs and symptoms score ( CPSSS ) and visual analogue scale , including statistical noninferiority to DMPA-SC in dysmenorrhea and nonmenstrual pelvic pain components of the CPSSS . The most common adverse events ( AEs ) in elagolix groups were headache , nausea , and nasopharyngitis , whereas the most common AEs in the DMPA-SC group were headache , nausea , upper respiratory tract infection , and mood swings . This study showed that similar to DMPA-SC , elagolix treatment had minimal impact on BMD over a 24-week period and demonstrated similar efficacy on endometriosis-associated pain
( S ) Few studies of medical therapies for endometriosis report outcomes that are relevant to patients , and many women gain only limited or intermittent benefit from treatment
OBJECTIVE To assess patient response rates to medical therapies used to treat endometriosis-associated pain .